Loading stock data…
Veraxa Biotech AG (VRXA)
$1.60-0.16 (-9.09%)
Market ClosedLast close Sep 8
VERAXA Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Veraxa Biotech AG in the Healthcare sector is trading at $1.60 with a market capitalization of $226M. The stock is currently near its 52-week low of $1.27, remaining 81.7% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 15/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q4 2025 | Q2 2025 | Q4 2024 |
|---|---|---|---|
| Total Revenue | — | — | — |
| Gross Profit | — | — | — |
| Operating Income | — | — | — |
| Net Income | — | — | — |
Peer Comparison
JNJUNHPFE
Fundamentals
VERAXA Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary t...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$226.25M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-
Volume
Today's trading volume
468,262
Recent News
The Cancer Therapy Strategy VERAXA Is Betting the Company On
By Karen Roman VERAXA Biotech AG (Nasdaq: VRXA) said it expects BiTAC molecules to be the company’s main value drivers and to dominate its pipeline development in the upcoming years, hence receiving VERAXA’s main share of investments to have a first BiTAC-T cell engager candidate ready by early 2028. The company stated its half-year progress […] The post The Cancer Therapy Strategy VERAXA Is Betting the Company On appeared first on ExecEdge.
VERAXA Biotech Stock in Focus as Lead Cancer Program Reaches Development Milestone
By Karen Roman VERAXA Biotech AG (Nasdaq: VRXA) said it started cell line development for its lead BiTAC T-cell engager program, collaborating with ATUM to apply proprietary technology for stable clonal cell line generation. “Today’s news underscores our commitment to accelerate the development path of our growing BiTAC-TCE portfolio,” said Christoph Erkel, Ph.D., VERAXA’s Vice […] The post VERAXA Biotech Stock in Focus as Lead Cancer Program Reaches Development Milestone appeared first on ExecE
VERAXA Biotech Expands R&D Hub in Heidelberg as Programs Advance Towards Clinical Development
By Daniella Parra VERAXA Biotech AG (Nasdaq: VRXA)has expanded its R&D facility in Heidelberg, Germany, increasing laboratory space by more than 60% to support team growth and accelerate its cancer therapy programs toward clinical development, the company said. The expansion strengthens research capabilities while allowing the company to remain in Heidelberg’s leading medical oncology hub […] The post VERAXA Biotech Expands R&D Hub in Heidelberg as Programs Advance Towards Clinical Development a
VERAXA Unveils Cancer Therapy Platform, Sparks Partnering Talks at BIO 2026
By Karen Roman Veraxa Biotech AG (Nasdaq: VRXA) reported in vitro proof-of-concept data validating its BiTAC-ADC platform for cancer therapies, with selective tumor cell killing while sparing healthy cells. The company will showcase partnering opportunities for its platform at the BIO International Convention in San Diego, California, taking place on June 22-25, 2026, it stated […] The post VERAXA Unveils Cancer Therapy Platform, Sparks Partnering Talks at BIO 2026 appeared first on ExecEdge.